Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

80%

4 of 5 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

N/A
6(100.0%)
6Total
N/A(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT03468309Completed

Medication Optimization Using Pharmacogenetic Testing and the G-DIG to Reduce Polypharmacy in a Mental Health Population

Role: collaborator

NCT01426516Not ApplicableTerminated

Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1)

Role: lead

NCT03113890Not ApplicableCompleted

McLean and Genomind Prospective Study

Role: collaborator

NCT02634177Not ApplicableCompleted

Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDD

Role: lead

NCT02566057Not ApplicableCompleted

Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis

Role: collaborator

NCT01507155Not ApplicableCompleted

An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay

Role: lead

NCT01438242Not ApplicableWithdrawn

An Open Label Study of the Genecept™ Assay in Treatment Resistant Depression

Role: lead

All 7 trials loaded